Long-term Survival of Multiple Myeloma Based on CBC Test at Diagnosis Using Defective Marshall-Olkin Cure Model
Archives of Advances in Biosciences,
Vol. 13 No. 1 (2022),
1 January 2022
,
Page 1-5
https://doi.org/10.22037/aab.v13i2.39613
Abstract
Introduction: As a malignant proliferative disorder, multiple myeloma (MM) is classified as a cancer of the immune system. Generally, a complete blood count (CBC) is the first test for a patient with symptoms of MM. Through CBC, physicians can monitor abnormalities in the blood. To normalize malignancies in their blood, patients must first go through conventional chemotherapy. Afterward, if eligible, subjects would receive high-dose therapy and hematopoietic stem cell transplantation (HSCT). Primarily, patients would be subjected to autologous hematopoietic stem cell transplantation (auto-HSCT).
Materials and Methods: This retrospective cohort study consisted of 56 MM patients who were diagnosed between January 2010 and August 2016 and were followed up until February 2022. The survival rate of MM patients was assessed based on CBC test at the time of diagnosis. The clinical conditions, i.e., Thrombocytopenia, Leukopenia, and Anemia, were extracted from the CBC test and were used as the desired prognostic factors in companion with age at diagnosis. Overall survival based on the mentioned factors was analyzed using the defective Marshall-Olkin gompertz cure model, which was programmed in R software version 4.0.3.
Results: The mean age at diagnosis was 52.76 (SD = 7.1). The probability of long-term survival for patients in this study was 46%, with five-year overall survival equaling 73.2%. Patients with thrombocytopenia had about 86% lower odds of long-term survival compared with patients with normal Platelet levels (Plt).
Conclusion: The present study indicates that deficiency in Plt count is a significant factor leading to poor survival of MM patients.
- Multiple myeloma, Long-term survival, Thrombocytopenia, Defective distributions
How to Cite
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021; 71(3):209–49. [DOI:10.3322/caac.21660] [PMID]
Mehta GR, Suhail F, Haddad RY, Zalzaleh G, Lerma E V. Multiple myeloma. Dis Mon. 2014; 60(10):483–8. [DOI:10.1016/J.DISAMONTH.2014.08.002] [PMID]
Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, et al. Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma. Blood. 2016; 128(13):1735–44. [DOI:10.1182/BLOOD-2016-06-723007] [PMID] [PMCID]
Dhakal B, Vesole DH, Hari PN. Allogeneic stem cell transplantation for multiple myeloma: is there a future? Bone Marrow Transplant. 2016; 51(4):492–500. [DOI:10.1038/BMT.2015.325] [PMID]
Holstein SA, McCarthy PL. Improved survival with salvage autologous stem-cell transplantation in myeloma. Lancet Haematol. 2016; 3(7):306–7. [DOI:10.
/S2352-3026(16)30058-8] [PMID]
Gay F, Oliva S, Petrucci MT, Montefusco V, Conticello C, Musto P, et al. Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis. Leukemia. 2017; 31(8):1727–34. [DOI:10.1038/LEU.2016.381] [PMID]
González-Calle V, Cerdá S, Labrador J, Sobejano E, González-Mena B, Aguilera C, et al. Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica. 2017; 102(5):922–31. [DOI:10.3324/
HAEMATOL.2016.158345] [PMID] [PMCID]
Merz M, Jansen L, Castro FA, Hillengass J, Salwender H, Weisel K, et al. Survival of elderly patients with multiple myeloma-Effect of upfront autologous stem cell transplantation. Eur J Cancer. 2016; 62:1–8. [DOI:10.
/J.EJCA.2016.04.004] [PMID]
Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, et al. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus
placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017; 4(9):431–42. [DOI:10.1016/S2352-3026(17)30140-0] [PMID] [PMCID]
Rocha R, Nadarajah S, Tomazella V, Louzada F. A new class of defective models based on the Marshall–Olkin family of distributions for cure rate modeling. Comput Stat Data Anal. 2017; 107:48–63. [DOI:10.1016/
j.csda.2016.10.001]
Lee ET, Wang JW. Statistical methods for survival data analysis. John Wiley & Sons; 2003.
Team RC. R: A Language and environment for statistical computing. Vienna, Austria; 2022.
Cleveland Clinic. Multiple Myeloma: Symptoms, What It Is, Prognosis & Treatment. Cleveland Clinic. 2022. Available From: https://my.clevelandclinic.org/
health/articles/6178-multiple-myeloma
Roshandel E, Kaviani S, Hajifathali A, Soleimani M. Pre-transplant thrombocytopenia predicts engraftment time and blood products requirement in allogeneic hematopoietic stem cell transplantation patients. Transfus Apher Sci. 2020; 59(4):102810. [DOI:10.1016/j.transci.2020.102810] [PMID]
Mittelman M. The implications of anemia in multiple myeloma. Clin Lymphoma. 2003; 4(1):23-9. [DOI:10.
/clm.2003.s.005] [PMID]
Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised international staging system for multiple myeloma: A report from international myeloma working group. J Clin Oncol. 2015; 33(26):2863–9. [DOI:10.1200/JCO.2015.61.2267]
Bringhen S, Mateos MV, Zweegman S, Larocca A, Falcone AP, Oriol A, et al. Age and organ damage correlate with poor survival in myeloma patients: Meta-analysis of 1435 individual patient data from 4 randomized trials. Haematologica. 2013; 98(6):980–7. [DOI:10.3324/haematol.2012.075051] [PMID] [PMCID]
Merchionne F, Procaccio P, Dammacco F. Long-term survival in multiple myeloma: A single-center experience. Clin Exp Med. 2008; 8(3):133–9. [DOI:10.1007/s10238-008-0169-8] [PMID]
Amico M, Van Keilegom I. Cure models in survival analysis. Annu Rev Stat Its Appl. 2018; 5(1):311–42. [DOI:10.1146/annurev-statistics-031017-100101]
Peng Y, Yu B. Cure models : methods, applications, and implementation. New York: Routledge; 2021. [DOI:10.1201/9780429032301]
Othus M, Barlogie B, LeBlanc ML, Crowley JJ. Cure models as a useful statistical tool for analyzing survival. Clin Cancer Res. 2012; 18(14):3731–6. [DOI:10.1158/1078-0432.CCR-11-2859] [PMID] [PMCID]
Ferreira Da Rocha R. Defective models for cure rate modeling. [PhdThesis]. University of S˜ao Carlos; 2016. https://repositorio.ufscar.br/handle/ufscar/7751
Balka J, Desmond AF, McNicholas PD. Bayesian and likelihood inference for cure rates based on defective inverse Gaussian regression models. J Appl Stat. 2011; 38(1):127–44. [DOI:10.1080/02664760903301127]
Balka J, Desmond AF, McNicholas PD. Review and implementation of cure models based on first hitting times for Wiener processes. Lifetime Data Anal. 2009; 15(2):147—176. [DOI:10.1007/s10985-008-9108-y]
Usmani SZ, Hoering A, Cavo M, Miguel JS, Goldschimdt H, Hajek R, et al. Clinical predictors of long-term survival in newly diagnosed transplant eligible multiple myeloma — an IMWG Research Project. Blood Cancer J. 2018; 8(12):1-7. [DOI:10.1038/s41408-018-0155-7] [PMID] [PMCID]
Ravi P, Kumar SK, Cerhan JR, Maurer MJ, Dingli D, Ansell SM, et al. Defining cure in multiple myeloma: A comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 2018; 8(3):1–7. [DOI:10.1038/s41408-018-0065-8] [PMID] [PMCID]
- Abstract Viewed: 234 times
- PDF Downloaded: 155 times
- MP3 Downloaded: 85 times